ATLANTA, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its founder and executive chairman, Jeff Arnold, and incoming chief executive officer, Brent Layton, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 10, 2024 at 8:15 a.m. PST.
A live audio webcast and replay of the event will be available online for a period of 30 days at https://investors.sharecare.com/news-and-events/events-and-presentations.
About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.
Media Relations:
Jen Martin Hall
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Darrell Thomas
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.43 |
Daily Volume: | 0 |
Market Cap: | US$531.790M |
September 10, 2024 August 09, 2024 March 28, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load